Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

In vivo liquid biopsy using Cytophone platform for photoacoustic detection of circulating tumor cells in patients with melanoma.

Galanzha EI, Menyaev YA, Yadem AC, Sarimollaoglu M, Juratli MA, Nedosekin DA, Foster SR, Jamshidi-Parsian A, Siegel ER, Makhoul I, Hutchins LF, Suen JY, Zharov VP.

Sci Transl Med. 2019 Jun 12;11(496). pii: eaat5857. doi: 10.1126/scitranslmed.aat5857. Erratum in: Sci Transl Med. 2019 Sep 18;11(510):.

PMID:
31189720
2.

Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study.

Larsen V, Barlow WE, Yang JJ, Zhu Q, Liu S, Kwan ML, Ergas IJ, Roh JM, Hutchins LF, Kadlubar SA, Albain KS, Rae JM, Yeh IT, Ravdin PM, Martino S, Lyss AP, Osborne CK, Hortobagyi GN, Kushi LH, Hayes DF, Ambrosone CB, Yao S.

Clin Breast Cancer. 2019 Aug;19(4):225-235.e2. doi: 10.1016/j.clbc.2019.02.010. Epub 2019 Mar 6.

PMID:
30928413
3.

Cancer patient perspectives regarding preparedness for end-of-life care: A qualitative study.

Sherman AC, Simonton-Atchley S, Mikeal CW, Anderson KM, Arnaoutakis K, Hutchins LF, Makhoul I, Mahmoud F, Milojkovic N, Harrington SE, Suen JY.

J Psychosoc Oncol. 2018 Jul-Aug;36(4):454-469. doi: 10.1080/07347332.2018.1466845. Epub 2018 Jun 4.

PMID:
29863447
4.

Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects.

Hutchins LF, Makhoul I, Emanuel PD, Pennisi A, Siegel ER, Jousheghany F, Guo X, Pashov AD, Monzavi-Karbassi B, Kieber-Emmons T.

Oncotarget. 2017 Oct 23;8(58):99161-99178. doi: 10.18632/oncotarget.21959. eCollection 2017 Nov 17.

5.

Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years.

Kaur V, Swami A, Alapat D, Abdallah AO, Motwani P, Hutchins LF, Jethava Y.

Hematology. 2018 Jan;23(1):17-24. doi: 10.1080/10245332.2017.1333275. Epub 2017 Jun 2.

PMID:
28574302
6.

Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Mahmoud F, Shields B, Makhoul I, Avaritt N, Wong HK, Hutchins LF, Shalin S, Tackett AJ.

Cancer Biol Ther. 2017 Jul 3;18(7):451-469. doi: 10.1080/15384047.2017.1323596. Epub 2017 May 17. Review.

7.

Managing Expectations in the Transition to Proof of Concept Studies.

Kieber-Emmons T, Makhoul I, Pennisi A, Siegel ER, Emanuel PD, Monzavi-Karbassi B, Steplewski Z, Beck JT, Hutchins LF.

Rev Recent Clin Trials. 2017;12(2):111-123. doi: 10.2174/1574887112666170321121250. Review.

PMID:
28325150
8.

Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.

Makhoul I, Todorova VK, Siegel ER, Erickson SW, Dhakal I, Raj VR, Lee JY, Orloff MS, Griffin RJ, Henry-Tillman RS, Klimberg S, Hutchins LF, Kadlubar SA.

PLoS One. 2017 Jan 3;12(1):e0168550. doi: 10.1371/journal.pone.0168550. eCollection 2017.

9.

Harnessing benefit from targeting tumor associated carbohydrate antigens.

Kieber-Emmons T, Monzavi-Karbassi B, Hutchins LF, Pennisi A, Makhoul I.

Hum Vaccin Immunother. 2017 Feb;13(2):323-331. doi: 10.1080/21645515.2017.1264789. Review.

10.

Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.

Mahmoud F, Shields B, Makhoul I, Hutchins LF, Shalin SC, Tackett AJ.

Cancer Biol Ther. 2016 Jun 2;17(6):579-91. doi: 10.1080/15384047.2016.1167291. Epub 2016 Apr 22. Review.

11.

Pre-diagnosis blood glucose and prognosis in women with breast cancer.

Monzavi-Karbassi B, Gentry R, Kaur V, Siegel ER, Jousheghany F, Medarametla S, Fuhrman BJ, Safar AM, Hutchins LF, Kieber-Emmons T.

Cancer Metab. 2016 Apr 6;4:7. doi: 10.1186/s40170-016-0147-7. eCollection 2016.

12.

Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination.

Coleman HN, Greenfield WW, Stratton SL, Vaughn R, Kieber A, Moerman-Herzog AM, Spencer HJ, Hitt WC, Quick CM, Hutchins LF, Mackintosh SG, Edmondson RD, Erickson SW, Nakagawa M.

Cancer Immunol Immunother. 2016 May;65(5):563-73. doi: 10.1007/s00262-016-1821-x. Epub 2016 Mar 15.

13.

Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm.

Klair JS, Girotra M, Hutchins LF, Caradine KD, Aduli F, Garcia-Saenz-de-Sicilia M.

Dig Dis Sci. 2016 Jul;61(7):2132-9. doi: 10.1007/s10620-016-4042-4. Epub 2016 Feb 5.

PMID:
26846115
14.

A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.

Greenfield WW, Stratton SL, Myrick RS, Vaughn R, Donnalley LM, Coleman HN, Mercado M, Moerman-Herzog AM, Spencer HJ, Andrews-Collins NR, Hitt WC, Low GM, Manning NA, McKelvey SS, Smith D, Smith MV, Phillips AM, Quick CM, Jeffus SK, Hutchins LF, Nakagawa M.

Oncoimmunology. 2015 May 27;4(10):e1031439. eCollection 2015 Oct.

15.

Rituximab and intermediate-purity plasma-derived factor VIII concentrate (KoateĀ®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.

Pandey S, Nakagawa M, Rosenbaum ER, Arnaoutakis K, Hutchins LF, Makhoul I, Milojkovic N, Cottler-Fox M.

J Clin Apher. 2015 Feb;30(1):50-4. doi: 10.1002/jca.21348. Epub 2014 Jul 17.

PMID:
25042026
16.

Vemurafenib-induced bilateral facial palsy.

Shailesh FN, Singh M, Tiwari U, Hutchins LF.

J Postgrad Med. 2014 Apr-Jun;60(2):187-8. doi: 10.4103/0022-3859.132339.

17.

Cancer survivorship training: a pilot study examining the educational gap in primary care medicine residency programs.

Susanibar S, Thrush CR, Khatri N, Hutchins LF.

J Cancer Surviv. 2014 Dec;8(4):565-70. doi: 10.1007/s11764-014-0366-2. Epub 2014 May 13.

PMID:
24820428
18.

Regression of orbital and choroidal metastases from melanoma after treatment with vemurafenib.

Ngo E, Hutchins LF, Gardner JM, Uwaydat SH.

Can J Ophthalmol. 2014 Apr;49(2):e49-52. doi: 10.1016/j.jcjo.2013.12.012. No abstract available.

PMID:
24767240
19.

Merkel Cell Carcinoma: Epidemiology, Target, and Therapy.

Hughes MP, Hardee ME, Cornelius LA, Hutchins LF, Becker JC, Gao L.

Curr Dermatol Rep. 2014 Jan 22;3:46-53. eCollection 2014. Review.

20.

High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.

Makhoul I, Griffin RJ, Siegel E, Lee J, Dhakal I, Raj V, Jamshidi-Parsian A, Klimberg S, Hutchins LF, Kadlubar S.

Am J Clin Oncol. 2016 Jun;39(3):248-54. doi: 10.1097/COC.0000000000000046.

21.

Treatment of metastatic melanoma with pazopanib: A report of five patient cases.

Dayer LE, Hutchins LF, Johnson JT.

J Oncol Pharm Pract. 2015 Jun;21(3):224-31. doi: 10.1177/1078155214524084. Epub 2014 Feb 27.

PMID:
24576945
22.

Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer.

Makhoul I, Klimberg VS, Korourian S, Henry-Tillman RS, Siegel ER, Westbrook KC, Hutchins LF.

Am J Clin Oncol. 2015 Feb;38(1):74-9. doi: 10.1097/COC.0b013e31828940c3.

PMID:
23563210
23.

A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316).

Javid SH, Unger JM, Gralow JR, Moinpour CM, Wozniak AJ, Goodwin JW, Lara PN Jr, Williams PA, Hutchins LF, Gotay CC, Albain KS.

Oncologist. 2012;17(9):1180-90. Epub 2012 Jun 20.

24.

Subjective sleep quality, objective sleep characteristics, insomnia symptom severity, and daytime sleepiness in women aged 50 and older with nonmetastatic breast cancer.

Enderlin CA, Coleman EA, Cole C, Richards KC, Kennedy RL, Goodwin JA, Hutchins LF, Mack K.

Oncol Nurs Forum. 2011 Jul;38(4):E314-25. doi: 10.1188/11.ONF.E314-E325.

PMID:
21708527
25.

Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.

Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff M, Hortobagyi GN, Hayes DF, Ambrosone CB.

Clin Cancer Res. 2010 Dec 15;16(24):6169-76. doi: 10.1158/1078-0432.CCR-10-0281.

26.

Palmar fasciitis with polyarthritis syndrome in a patient with breast cancer.

Krishna K, Yacoub A, Hutchins LF, Kortebein PM.

Clin Rheumatol. 2011 Apr;30(4):569-72. doi: 10.1007/s10067-010-1592-2. Epub 2010 Oct 16. Review.

PMID:
20953809
27.

Celiac crisis in a patient with chronic lymphocytic leukemia and hypogammaglobulinemia.

Krishna K, Krishna SG, Coviello-malle JM, Yacoub A, Hutchins LF.

Clin Res Hepatol Gastroenterol. 2011 Jan;35(1):70-3. doi: 10.1016/j.gcb.2010.08.002.

PMID:
20822871
28.

Sleep across chemotherapy treatment: a growing concern for women older than 50 with breast cancer.

Enderlin CA, Coleman EA, Cole C, Richards KC, Hutchins LF, Sherman AC.

Oncol Nurs Forum. 2010 Jul;37(4):461-A3. doi: 10.1188/10.ONF.461-468. Review.

PMID:
20591805
29.

Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer.

Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hortobagyi GN, Hayes DF, Ambrosone CB.

Breast Cancer Res Treat. 2010 Nov;124(2):433-9. doi: 10.1007/s10549-010-0840-0. Epub 2010 Mar 23.

30.

Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.

Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, Liu PY, Thompson JA, Flaherty LE, Sondak VK.

Cancer. 2010 Jan 15;116(2):424-31. doi: 10.1002/cncr.24739.

31.

Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.

Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hayes DF, Ambrosone CB.

Clin Cancer Res. 2009 Aug 15;15(16):5258-66. doi: 10.1158/1078-0432.CCR-09-0685. Epub 2009 Aug 11.

32.

Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897.

Hershman DL, Unger JM, Barlow WE, Hutchins LF, Martino S, Osborne CK, Livingston RB, Albain KS.

J Clin Oncol. 2009 May 1;27(13):2157-62. doi: 10.1200/JCO.2008.19.1163. Epub 2009 Mar 23.

33.

Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates.

Wang-Gillam A, Miles DA, Hutchins LF.

Oncologist. 2008 Jul;13(7):821-7. doi: 10.1634/theoncologist.2008-0013. Epub 2008 Jul 9.

34.

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer CE Jr, Costantino JP, Wolmark N.

J Clin Oncol. 2008 Apr 20;26(12):1965-71. doi: 10.1200/JCO.2007.14.0228. Epub 2008 Mar 10.

PMID:
18332472
35.

Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.

Ganz PA, Hussey MA, Moinpour CM, Unger JM, Hutchins LF, Dakhil SR, Giguere JK, Goodwin JW, Martino S, Albain KS.

J Clin Oncol. 2008 Mar 10;26(8):1223-30. doi: 10.1200/JCO.2007.11.8877. Epub 2008 Jan 28.

PMID:
18227530
36.

Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026.

Hutchins LF, Moon J, Clark JI, Thompson JA, Lange MK, Flaherty LE, Sondak VK.

Cancer. 2007 Nov 15;110(10):2269-75.

37.

Barriers to clinical trials vary according to the type of trial and the institution.

Govindarajan R, Young JW, Harless CL, Hutchins LF.

J Clin Oncol. 2007 Apr 20;25(12):1633-4; author reply 1634. No abstract available.

PMID:
17443010
38.

Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).

Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge GW Jr, Shapiro CL, Ingle JN, Lew D, Hutchins LF, Livingston RB, Martino S.

J Clin Oncol. 2007 Feb 20;25(6):656-61.

PMID:
17308269
39.

Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma.

Monzavi-Karbassi B, Hennings LJ, Artaud C, Liu T, Jousheghany F, Pashov A, Murali R, Hutchins LF, Kieber-Emmons T.

Vaccine. 2007 Apr 20;25(16):3022-31. Epub 2007 Jan 26.

PMID:
17303294
40.

Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials.

Unger JM, Coltman CA Jr, Crowley JJ, Hutchins LF, Martino S, Livingston RB, Macdonald JS, Blanke CD, Gandara DR, Crawford ED, Albain KS.

J Clin Oncol. 2006 Jan 1;24(1):141-4. Epub 2005 Dec 5.

PMID:
16330670
41.
42.

Methylation profiling of archived non-small cell lung cancer: a promising prognostic system.

Safar AM, Spencer H 3rd, Su X, Coffey M, Cooney CA, Ratnasinghe LD, Hutchins LF, Fan CY.

Clin Cancer Res. 2005 Jun 15;11(12):4400-5.

43.

Metastatic renal cell carcinoma to prostate.

Greene GF, Gokden N, Hutchins LF, Williams RC.

Urology. 2005 Jun;65(6):1227.

PMID:
15922439
44.

Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.

Pierce LJ, Hutchins LF, Green SR, Lew DL, Gralow JR, Livingston RB, Osborne CK, Albain KS.

J Clin Oncol. 2005 Jan 1;23(1):24-9. Epub 2004 Nov 15.

PMID:
15545669
45.

The academic hematology-oncology firm:a model for postgraduate cancer education.

Kohli M, Zent C, Hutchins LF, Safar M, Dotson P, Mehta P.

J Cancer Educ. 2004 Spring;19(1):45-9.

PMID:
15059755
46.

Racial differences in the outcome of patients with colorectal carcinoma.

Govindarajan R, Shah RV, Erkman LG, Hutchins LF.

Cancer. 2003 Jan 15;97(2):493-8.

47.

Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment.

Sweeney C, Ambrosone CB, Joseph L, Stone A, Hutchins LF, Kadlubar FF, Coles BF.

Int J Cancer. 2003 Mar 1;103(6):810-4.

48.

Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy.

Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF, Kadlubar FF, Ambrosone CB.

J Natl Cancer Inst. 2002 Nov 6;94(21):1635-40.

PMID:
12419790
49.

Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology Group.

Budd GT, Rankin C, Hutchins LF, Wong L, Petruska PJ, Antman K; Southwest Oncology Group.

Invest New Drugs. 2002 Feb;20(1):129-32.

PMID:
12003189
50.

Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer.

Ambrosone CB, Sweeney C, Coles BF, Thompson PA, McClure GY, Korourian S, Fares MY, Stone A, Kadlubar FF, Hutchins LF.

Cancer Res. 2001 Oct 1;61(19):7130-5.

Supplemental Content

Loading ...
Support Center